In another murine TNBC model (EMT‐6), which also had high expression of TfR1 as 4T1 model (Figure S36, Supporting Information), the tumor growth was inhibited by 77% after DoxFILN treatment (Figure 6e), and the MST of mice was extended from 16 days (PBS group) to 42 days (Figure 6f), confirming that DoxFILN was a potential treatment for TNBC. This evidence concerns the gene TFRC and neoplasm.